Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 07, 2025 07:00 ET | Source: OMass Therapeutics

OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025

Oxford, United Kingdom – 7th July 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane...
October 01, 2024 02:30 ET | Source: OMass Therapeutics

OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2

PRESS RELEASE OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2 Oxford, United Kingdom – 1 October 2024 –...
August 05, 2024 09:08 ET | Source: OMass Therapeutics

OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024

PRESS RELEASE OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024 Oxford, United Kingdom – 5th August 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology...
August 02, 2023 02:00 ET | Source: OMass Therapeutics

OMass Therapeutics Expands Leadership Team with Two New Appointments

PRESS RELEASE OMass Therapeutics Expands Leadership Team with Two New Appointments Appointment of two senior executives in newly created rolesPeter Phillips M.D., Ph.D. joins as Senior Vice...
April 28, 2022 02:00 ET | Source: OMass Therapeutics

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases

PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi...